Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
Holding MGX?
Track your performance easily
MGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $12.74
Previous CloseN/A
Volume382.73K
Average Volume (3M)3.51M
Market Cap
$103.29M
Enterprise Value-$148.73M
Total Cash (Recent Filing)$108.15M
Total Debt (Recent Filing)$17.96M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 26, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding37,423,916
10 Day Avg. Volume724,489
30 Day Avg. Volume3,509,658
Standard Deviation0.32
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.55
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.44
Enterprise Value/Revenue-4.72
Enterprise Value/Gross Profit-8.65
Enterprise Value/Ebitda4.15
Forecast
1Y Price Target
$19.25Price Target Upside597.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Metagenomi, Inc. News
PremiumStock Analysis & Ideas
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Metagenomi Reports Q3 Earnings and Strategic ProgressBulls Say, Bears Say
Bulls Say
Financial StabilityMGX's cash position is expected to fund operations into 2027, indicating strong financial stability and reduced risk for investors.
Gene Therapy AdvancementsMGX's novel FVIII with 5-10x secretion/activity boost garnered strong interest, marking a significant advancement in gene therapy for Hemophilia A.
Market ValuationMetagenomi trades at a discount to cash, mitigating risk and presenting a potentially undervalued opportunity for investors interested in genetic medicines.
Bears Say
Clinical DataRisks include delays in advancing pipeline candidates into and through clinical assessment and failure to generate favorable clinical data from ongoing programs.
Clinical TrialsThere is a 20% probability of approval for both the Hemophilia A and transthyretin amyloidosis programs, which indicates conservative expectations.
Pipeline RisksRisks include, but are not limited to: delays in advancing pipeline candidates into and through clinical assessment; failure to generate favorable clinical data from ongoing programs, particularly in Hemophilia A and TTR; and possible long-term dilution risk.
---
Ownership Overview
33.32% Insiders
1.64% Mutual Funds
0.06% Other Institutional Investors
60.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MGX FAQ
What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $1.61 and its highest was $12.74 in the past 12 months.
What is Metagenomi, Inc.’s market cap?
Metagenomi, Inc.’s market cap is $103.29M.
When is Metagenomi, Inc.’s upcoming earnings report date?
Metagenomi, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 70 days.
How were Metagenomi, Inc.’s earnings last quarter?
Metagenomi, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.776 by $0.266.
Is Metagenomi, Inc. overvalued?
According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued.
Does Metagenomi, Inc. pay dividends?
Metagenomi, Inc. does not currently pay dividends.
What is Metagenomi, Inc.’s EPS estimate?
Metagenomi, Inc.’s EPS estimate is -0.75.
How many shares outstanding does Metagenomi, Inc. have?
Metagenomi, Inc. has 37,423,916 shares outstanding.
What happened to Metagenomi, Inc.’s price movement after its last earnings report?
Metagenomi, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.776. Following the earnings report the stock price went down -10.9%.
Which hedge fund is a major shareholder of Metagenomi, Inc.?
Currently, no hedge funds are holding shares in MGX
---
Metagenomi, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.25 (597.46% Upside)
$19.25 (597.46% Upside)
Hedge Fund Trend
Decreased
By 458.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Fundamentals
Return on Equity
-28.91%
Trailing 12-Months
Asset Growth
-7.27%
Trailing 12-Months
Company Description
Metagenomi, Inc.
Metagenomi, Inc. (MGX) is a biotechnology company focused on advancing the field of gene editing. The company operates within the healthcare and life sciences sectors, leveraging its proprietary technology platform to discover and develop novel gene-editing systems. Metagenomi's core services involve providing customized gene-editing solutions for a variety of applications, including therapeutic development, agricultural biotechnology, and industrial biotechnology.
---
MGX Stock 12 Month Forecast
Average Price Target
$19.25
▲(597.46% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering MGX
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-3.46%
reiterated a buy rating last month
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -3.46% per trade.
---